Safety aspects of GH replacement.
In adults, GH replacement therapy will often be maintained for decades. Owing to the long duration of GH replacement in many adults, it is essential to establish the long-term safety aspects of the treatment. In this review, studies that have investigated the safety profile of long-term GH replacement will be reviewed with an emphasis on studies based on data from the Pfizer International Metabolic Database (KIMS). These studies show that long-term GH replacement in adults is safe and that long-term GH replacement may even improve cardiovascular mortality and morbidity in GH-deficient adults.
Svensson
Johan
J
Department of Endocrinology, Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden. johan.svensson@medic.gu.se <johan.svensson@medic.gu.se>
Bengtsson
Bengt-Ake
BA
D000328:Adult; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced / Q000453:epidemiology* / Q000378:metabolism; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency*; D006801:Humans; D007029:Hypothalamic Neoplasms / Q000453:epidemiology; D007328:Insulin / Q000378:metabolism; D007391:International Cooperation; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D010911:Pituitary Neoplasms / Q000453:epidemiology; D018570:Risk Assessment; D012307:Risk Factors
D007328:Insulin; D019382:Human Growth Hormone